GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » 3-Year FCF Growth Rate

CollPlant Biotechnologies (XTAE:CLGN) 3-Year FCF Growth Rate : 23.30% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies 3-Year FCF Growth Rate?

CollPlant Biotechnologies's Free Cash Flow per Share for the three months ended in Dec. 2023 was ₪-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of CollPlant Biotechnologies was 27.70% per year. The lowest was -257.10% per year. And the median was -21.25% per year.


Competitive Comparison of CollPlant Biotechnologies's 3-Year FCF Growth Rate

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year FCF Growth Rate falls into.



CollPlant Biotechnologies 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


CollPlant Biotechnologies  (XTAE:CLGN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


CollPlant Biotechnologies 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (XTAE:CLGN) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.